Modality
siRNA
MOA
PLK4i
Target
GPRC5D
Pathway
NF-κB
Psoriasis
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
~Jul 2018
→ ~Oct 2019
Phase 2
~Jan 2020
→ ~Apr 2021
Phase 3
Jul 2021
→ Dec 2031
Phase 3Current
NCT07862714
1,327 pts·Psoriasis
2025-09→2031-12·Terminated
NCT06457323
1,369 pts·Psoriasis
2022-07→2028-04·Recruiting
NCT04794646
590 pts·Psoriasis
2021-07→2025-08·Recruiting
3,286 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-08-277mo agoPh3 Readout· Psoriasis
2028-04-052.0y awayPh3 Readout· Psoriasis
2031-12-105.7y awayPh3 Readout· Psoriasis
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Recruit…
P3
Recruit…
P3
Termina…
Catalysts
Ph3 Readout
2025-08-27 · 7mo ago
Psoriasis
Ph3 Readout
2028-04-05 · 2.0y away
Psoriasis
Ph3 Readout
2031-12-10 · 5.7y away
Psoriasis
RecruitingTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07862714 | Phase 3 | Psoriasis | Terminated | 1327 | HbA1c |
| NCT06457323 | Phase 3 | Psoriasis | Recruiting | 1369 | DOR |
| NCT04794646 | Phase 3 | Psoriasis | Recruiting | 590 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| ASN-7408 | Ascendis Pharma | NDA/BLA | GPRC5D |